report cover

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Insights and Forecast to 2028

  • 06 April 2022
  • Life Sciences
  • 109 Pages
  • Report code : 24WT-6979350

Diphtheria Tetanus and Pertussis Vaccine Market

1 Study Coverage
1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Immune DTaP Vaccine
1.2.3 Therapy DTaP Vaccine
1.3 Market by Application
1.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Adult
1.3.3 Pediatric
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region
2.4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Region (2023-2028)
2.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region
2.5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022)
2.5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturers
3.1.1 Global Top Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in 2021
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers
3.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue in 2021
3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
4.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type
4.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type
4.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2022)
4.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
5.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application
5.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application
5.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2022)
5.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
6.1.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
6.1.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
6.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
6.2.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
6.2.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
6.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
6.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2028)
6.3.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
7.1.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
7.1.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
7.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
7.2.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
7.2.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
7.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
7.3.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2028)
7.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
8.1.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
8.2.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region
8.3.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
9.1.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
9.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
9.2.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
9.3 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
9.3.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
10.1.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
10.2.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
10.3.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Sanofi Pasteur
11.1.1 Sanofi Pasteur Corporation Information
11.1.2 Sanofi Pasteur Overview
11.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi Pasteur Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Corporation Information
11.2.2 GlaxoSmithKline Overview
11.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GlaxoSmithKline Recent Developments
11.3 Protein Sciences Corporation
11.3.1 Protein Sciences Corporation Corporation Information
11.3.2 Protein Sciences Corporation Overview
11.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Protein Sciences Corporation Recent Developments
11.4 Novartis AG
11.4.1 Novartis AG Corporation Information
11.4.2 Novartis AG Overview
11.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novartis AG Recent Developments
11.5 Seqirus
11.5.1 Seqirus Corporation Information
11.5.2 Seqirus Overview
11.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Seqirus Recent Developments
11.6 Merck Sharp & Dohme Corp
11.6.1 Merck Sharp & Dohme Corp Corporation Information
11.6.2 Merck Sharp & Dohme Corp Overview
11.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Merck Sharp & Dohme Corp Recent Developments
11.7 Astellas Pharma US
11.7.1 Astellas Pharma US Corporation Information
11.7.2 Astellas Pharma US Overview
11.7.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Astellas Pharma US Recent Developments
11.8 Pfizer Inc
11.8.1 Pfizer Inc Corporation Information
11.8.2 Pfizer Inc Overview
11.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Pfizer Inc Recent Developments
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Corporation Information
11.9.2 Johnson & Johnson Overview
11.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Johnson & Johnson Recent Developments
11.10 Lanzhou Institute of Biological Products Co., Ltd
11.10.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
11.10.2 Lanzhou Institute of Biological Products Co., Ltd Overview
11.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
11.11 AstraZeneca
11.11.1 AstraZeneca Corporation Information
11.11.2 AstraZeneca Overview
11.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 AstraZeneca Recent Developments
11.12 Emergent BioSolutions Inc
11.12.1 Emergent BioSolutions Inc Corporation Information
11.12.2 Emergent BioSolutions Inc Overview
11.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Emergent BioSolutions Inc Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Chain Analysis
12.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process
12.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Marketing
12.4.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Channels
12.4.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
12.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
13.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
13.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
13.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
14 Key Findings in The Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Ask Our Expert

Leave This Empty:

*Required Information
List of Tables
Table 1. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Immune DTaP Vaccine
Table 3. Major Manufacturers of Therapy DTaP Vaccine
Table 4. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
Table 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2022)
Table 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2023-2028) & (K Doses)
Table 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2023-2028)
Table 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2017-2022)
Table 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2023-2028)
Table 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturers (2017-2022) & (K Doses)
Table 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Manufacturers (2017-2022)
Table 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Manufacturers (2017-2022)
Table 18. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Manufacturers (2017-2022) &(USD/Dose)
Table 19. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine as of 2021)
Table 21. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 23. Date of Manufacturers Enter into Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 26. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Type (2017-2022)
Table 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Type (2023-2028)
Table 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2017-2022)
Table 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2023-2028)
Table 33. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2022) & (USD/Dose)
Table 34. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Type (2023-2028) & (USD/Dose)
Table 35. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 36. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 37. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Application (2017-2022)
Table 38. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Application (2023-2028)
Table 39. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2017-2022)
Table 42. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2023-2028)
Table 43. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2022) & (USD/Dose)
Table 44. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Application (2023-2028) & (USD/Dose)
Table 45. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 46. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 47. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 50. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 51. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 54. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 55. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 58. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 59. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 62. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 63. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 66. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 67. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 70. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 71. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 74. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 75. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
Table 78. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2023-2028) & (K Doses)
Table 79. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 82. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 83. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 86. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 87. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 90. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 91. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 94. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 95. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 98. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 99. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 102. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 103. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 105. Sanofi Pasteur Corporation Information
Table 106. Sanofi Pasteur Description and Major Businesses
Table 107. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 108. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Sanofi Pasteur Recent Developments
Table 110. GlaxoSmithKline Corporation Information
Table 111. GlaxoSmithKline Description and Major Businesses
Table 112. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 113. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. GlaxoSmithKline Recent Developments
Table 115. Protein Sciences Corporation Corporation Information
Table 116. Protein Sciences Corporation Description and Major Businesses
Table 117. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 118. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Protein Sciences Corporation Recent Developments
Table 120. Novartis AG Corporation Information
Table 121. Novartis AG Description and Major Businesses
Table 122. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 123. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Novartis AG Recent Developments
Table 125. Seqirus Corporation Information
Table 126. Seqirus Description and Major Businesses
Table 127. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 128. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Seqirus Recent Developments
Table 130. Merck Sharp & Dohme Corp Corporation Information
Table 131. Merck Sharp & Dohme Corp Description and Major Businesses
Table 132. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 133. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Merck Sharp & Dohme Corp Recent Developments
Table 135. Astellas Pharma US Corporation Information
Table 136. Astellas Pharma US Description and Major Businesses
Table 137. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 138. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Astellas Pharma US Recent Developments
Table 140. Pfizer Inc Corporation Information
Table 141. Pfizer Inc Description and Major Businesses
Table 142. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 143. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Pfizer Inc Recent Developments
Table 145. Johnson & Johnson Corporation Information
Table 146. Johnson & Johnson Description and Major Businesses
Table 147. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 148. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 149. Johnson & Johnson Recent Developments
Table 150. Lanzhou Institute of Biological Products Co., Ltd Corporation Information
Table 151. Lanzhou Institute of Biological Products Co., Ltd Description and Major Businesses
Table 152. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 153. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 154. Lanzhou Institute of Biological Products Co., Ltd Recent Developments
Table 155. AstraZeneca Corporation Information
Table 156. AstraZeneca Description and Major Businesses
Table 157. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 158. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 159. AstraZeneca Recent Developments
Table 160. Emergent BioSolutions Inc Corporation Information
Table 161. Emergent BioSolutions Inc Description and Major Businesses
Table 162. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 163. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 164. Emergent BioSolutions Inc Recent Developments
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List
Table 168. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers List
Table 169. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Trends
Table 170. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
Table 171. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
Table 172. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Picture
Figure 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Type in 2021 & 2028
Figure 3. Immune DTaP Vaccine Product Picture
Figure 4. Therapy DTaP Vaccine Product Picture
Figure 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Application in 2021 & 2028
Figure 6. Adult
Figure 7. Pediatric
Figure 8. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Report Years Considered
Figure 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2017-2028 (K Doses)
Figure 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2017-2028 (US$ Million)
Figure 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2022)
Figure 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2023-2028)
Figure 15. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 16. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 17. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 18. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 20. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 22. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 24. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 25. The Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 26. The Top 5 and 10 Largest Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in the World: Market Share by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue in 2021
Figure 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
Figure 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
Figure 32. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 33. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
Figure 34. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 35. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
Figure 36. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country (2017-2028)
Figure 37. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2017-2028)
Figure 38. U.S. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 39. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 40. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 41. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
Figure 42. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 43. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
Figure 44. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country (2017-2028)
Figure 45. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2017-2028)
Figure 46. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 47. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 48. U.K. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 49. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 50. Russia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 51. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 52. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
Figure 53. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 54. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
Figure 55. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Region (2017-2028)
Figure 56. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Region (2017-2028)
Figure 57. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 58. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 59. South Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 60. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 61. Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 62. Taiwan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 63. Indonesia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 64. Thailand Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 65. Malaysia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 66. Philippines Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 67. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 68. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
Figure 69. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 70. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
Figure 71. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country (2017-2028)
Figure 72. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2017-2028)
Figure 73. Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 74. Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 75. Argentina Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 76. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 79. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country (2017-2028)
Figure 81. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2017-2028)
Figure 82. Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 83. Saudi Arabia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 84. U.A.E Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (US$ Million)
Figure 85. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Value Chain
Figure 86. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed

Buy Full Report

Select Licence type with your requirement and needs

SECURITY ASSUREDpayment image

analyst icon
Still not found what you want?

Speak to our Custom Research Team and get the Custom Research in a budget

Custom Research


Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

WHY CHOOSE US

  • Proactive We manage our resources 24/7 to identify issues and address them before they become problems
  • Quality & Reliability We are committed to providing reliable and highly accurate data with an excellent quality control system
  • Global Outreach 6 Major regions and 40+ countries level analysis accomplished
  • Competitive Pricing Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

SAMPLE REPORT INCLUDES
  • Industry Market SizeIndustry Market Size
  • SWOT AnalysisSWOT Analysis
  • Industry Major PlayersIndustry Major Players
  • Revenue ForecastsRevenue Forecasts
  • Historical and Forecast GrowthHistorical and Forecast Growth
  • Profitability AnalysisProfitability Analysis
SOME OF OUR CLIENTS
WHAT SET US APART?
  • quilty

    Quality Assurance

    Focus on Data Accuracy & Reliability
  • quilty

    Trusted by the Best

    75+ Clients in Fortune 500
  • quilty

    Privacy and Security

    All your transactions are secured end-to-end, ensuring a satisfactory purchase
  • quilty

    Competitive Pricing

    Ensure the best and affordable pricing
OUR HAPPY CUSTOMER Some of our customer review
Stay Updated About Diphtheria Tetanus and Pertussis Vaccine Market

Leave This Empty: